Drugs / PhtD vaccine candidate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01444001 | Feb → Aug 2007 | streptococcal pneumonia | Sanofi | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PhtD vaccine candidate | “RESULTS: Sixty-three participants were enrolled and received the pilot safety dose (n=3) or at least 1 dose of PhtD vaccine candidate at 6 μg (n=20), 25 μg (n=20), or 100 μg (n=20).” PMID 23131206 ↗ Nov 2012 |
| Known as | PhtD | “OBJECTIVE: To explore safety and immunogenicity of a recombinant protein vaccine candidate against S. pneumoniae composed of adjuvanted pneumococcal histidine triad protein D (PhtD).” PMID 23131206 ↗ Nov 2012 |
| Modality | Protein / enzyme biologic | “recombinant protein vaccine candidate” PMID 23131206 ↗ Nov 2012 |